Literature DB >> 8473875

Stability in backward masking performance in schizophrenics, affectively disturbed patients, and normal subjects.

B R Rund1, N I Landrø, A L Orbeck.   

Abstract

The purpose of the present longitudinal study was to investigate the stability of backward masking performance in schizophrenics and nonschizophrenic psychotic patients. Twenty-two schizophrenics, eight nonschizophrenics, and 14 normal controls were tested three times, with an interval of 1 year between each test session. A standard stimulus duration procedure was used. The relative onset intervals between the target and the mask was 16.5 msec or 33 msec. A no mask condition was presented before the two masking conditions. Results showed that masking performance is a stable phenomenon, for both psychiatric groups and for normal controls. Significant differences were found between schizophrenics and the normal controls, but not between the two psychiatric groups. Vulnerability to masking stimuli as a specific characteristic for schizophrenics is, thus, not supported in the present study. The results suggest that backward masking deficit is an enduring feature of psychotic disturbances.

Entities:  

Mesh:

Year:  1993        PMID: 8473875     DOI: 10.1097/00005053-199304000-00004

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  12 in total

1.  Pupillometric measures of attentional allocation to target and mask processing on the backward masking task in schizophrenia.

Authors:  Eric Granholm; Scott C Fish; Steven P Verney
Journal:  Psychophysiology       Date:  2009-05       Impact factor: 4.016

2.  Fragile early visual percepts mark genetic liability specific to schizophrenia.

Authors:  Scott R Sponheim; Sarah M Sass; Althea L Noukki; Bridget M Hegeman
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

3.  Intact and deficient feature fusion in schizophrenia.

Authors:  Andreas Brand; Sabine Kopmann; Sonja Marbach; Martin Heinze; Michael H Herzog
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-05-04       Impact factor: 5.270

4.  Visual information processing dysfunction across the developmental course of early psychosis.

Authors:  V B Perez; K M Shafer; K S Cadenhead
Journal:  Psychol Med       Date:  2012-04-03       Impact factor: 7.723

5.  Early visual information processing deficit in depression with and without Borderline Personality Disorder.

Authors:  John G Keilp; H Marie Klain; Beth Brodsky; Maria A Oquendo; Marianne Gorlyn; Barbara Stanley; J John Mann
Journal:  Psychiatry Res       Date:  2006-11-09       Impact factor: 3.222

6.  Stability of visual masking performance in recent-onset schizophrenia: an 18-month longitudinal study.

Authors:  Junghee Lee; Keith H Nuechterlein; Kenneth L Subotnik; Catherine A Sugar; Joseph Ventura; Denise Gretchen-Doorly; Kimberly Kelly; Michael F Green
Journal:  Schizophr Res       Date:  2008-05-01       Impact factor: 4.939

7.  Impaired visual working memory consolidation in schizophrenia.

Authors:  Rebecca L Fuller; Steven J Luck; Elsie L Braun; Benjamin M Robinson; Robert P McMahon; James M Gold
Journal:  Neuropsychology       Date:  2009-01       Impact factor: 3.295

8.  Intact feature fusion in schizophrenic patients.

Authors:  Andreas Brand; Sabine Kopmann; Michael Herzog
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

9.  Neural Compensation Mechanisms of Siblings of Schizophrenia Patients as Revealed by High-Density EEG.

Authors:  Janir R da Cruz; Albulena Shaqiri; Maya Roinishvili; Ophélie Favrod; Eka Chkonia; Andreas Brand; Patrícia Figueiredo; Michael H Herzog
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

10.  The shine-through masking paradigm is a potential endophenotype of schizophrenia.

Authors:  Eka Chkonia; Maya Roinishvili; Natia Makhatadze; Lidia Tsverava; Andrea Stroux; Konrad Neumann; Michael H Herzog; Andreas Brand
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.